ArticlePCN reports : psychiatry and clinical neurosciences2026
Protocol of a single-arm open-label pilot study of extended rTMS therapy for treatment-resistant depression (ExTMS study).
Article in PCN reports : psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression (TRD) has been covered by the Japanese public health insurance system. Standard public insurance-covered treatment is limited to a 30-session course delivered over 8 weeks. While rTMS therapy is effective for TRD, residual depressive symptoms frequently persist after treatment completion. This pilot study aims to prospectively evaluate whether extended rTMS therapy can further improve depressive symptoms and be safely administered in patients with TRD who have shown insufficient improvement after completion of the standard treatment course. Methods: This is a 4-week single-arm open-label pilot study. Participants will be recruited from patients receiving standard public health insurance-covered rTMS therapy. Eligible participants are adults who achieved at least 20% improvement following the standard 30-session course but continue to experience residual depressive symptoms, defined as a 17-item Hamilton Depression Rating Scale (HAMD-17) total score of 5 or higher. Extended rTMS therapy will consist of 12 additional sessions administered over 4 weeks using the same stimulation protocol as the standard rTMS therapy. Outcomes: The primary outcome is the change in HAMD-17 total score from baseline, defined as completion of the standard 30-session course, to completion of extended treatment. Secondary outcomes include remission and minimal residual symptom rates, changes in depressive symptoms and patient-reported outcomes during treatment, and adverse events. Conclusions: This study will provide preliminary evidence regarding the potential clinical benefit of extended rTMS therapy for patients with residual depressive symptoms after completion of the standard treatment course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.